Other News To Note
Thursday, April 11, 2013
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said it will receive a $3.5 million grant from the National Institute of Allergy and Infectious Diseases to advance the development of its next-generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.